Barely Significant
← all excerpts

The current treatment landscape in the UK for stage III NSCLC.

Br J Cancer · 2020 · PMC7735211 · PMID 33293670

Europe PMCDOI
1
hedged sentence
0.0680
closest p · 1.4× alpha
0.0680
boldest claim

The sentences

showed a trendp = 0.068so close (0.05 < p ≤ 0.1)
29 One meta-analysis of trimodality treatment with surgery versus definitive CRT (concurrent or sequential not specified) showed a trend towards a survival benefit with trimodality treatment (HR 0.87; 95% CI 0.75–1.01; p = 0.068). 30 Guideline recommendations for stage III NSCLC There are a number of local and international guidelines providing recommendations on the treatment of stage III NSCLC. 15 , 24 , 31 There are some areas of consensus opinion including recommending definitive CRT in unresectable stage III NSCLC and other areas with less consensus.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.